Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects
Wegovy coverage depends on whether a plan includes weight-loss benefits, which many do not
Regular review ensures treatment remains appropriate and effective, with adjustments made according to symptom response and individual needs
Tara Narula during the segment
Report these or any other negative side effects to us
1 To understand whether non-diabetic patients prescribed GLP-1 medications experience similar rates of these gastrointestinal (GI) side effects, we studied 367,439 non-diabetic patients, including 170,842 who were on a GLP-1 medication and 196,597 who were on other weight loss medications